Current status of precision oncology in adult glioblastoma.
biomarker
glioblastoma
molecular profiling
personalized medicine
precision oncology
targeted treatment
Journal
Molecular oncology
ISSN: 1878-0261
Titre abrégé: Mol Oncol
Pays: United States
ID NLM: 101308230
Informations de publication
Date de publication:
20 Jun 2024
20 Jun 2024
Historique:
revised:
05
04
2024
received:
16
11
2023
accepted:
28
05
2024
medline:
20
6
2024
pubmed:
20
6
2024
entrez:
20
6
2024
Statut:
aheadofprint
Résumé
The concept of precision oncology, the application of targeted drugs based on comprehensive molecular profiling, has revolutionized treatment strategies in oncology. This review summarizes the current status of precision oncology in glioblastoma (GBM), the most common and aggressive primary brain tumor in adults with a median survival below 2 years. Targeted treatments without prior target verification have consistently failed. Patients with BRAF V600E-mutated GBM benefit from BRAF/MEK-inhibition, whereas targeting EGFR alterations was unsuccessful due to poor tumor penetration, tumor cell heterogeneity, and pathway redundancies. Systematic screening for actionable molecular alterations resulted in low rates (< 10%) of targeted treatments. Efficacy was observed in one-third and currently appears to be limited to BRAF-, VEGFR-, and mTOR-directed treatments. Advancing precision oncology for GBM requires consideration of pathways instead of single alterations, new trial concepts enabling rapid and adaptive drug evaluation, a focus on drugs with sufficient bioavailability in the CNS, and the extension of target discovery and validation to the tumor microenvironment, tumor cell networks, and their interaction with immune cells and neurons.
Identifiants
pubmed: 38899374
doi: 10.1002/1878-0261.13678
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 The Author(s). Molecular Oncology published by John Wiley & Sons Ltd on behalf of Federation of European Biochemical Societies.
Références
Malone ER, Oliva M, Sabatini PJB, Stockley TL, Siu LL. Molecular profiling for precision cancer therapies. Genome Med. 2020;12(1):8.
Le Tourneau C, Borcoman E, Kamal M. Molecular profiling in precision medicine oncology. Nat Med. 2019;25(5):711–712.
Mateo J, Chakravarty D, Dienstmann R, Jezdic S, Gonzalez‐Perez A, Lopez‐Bigas N, et al. A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO scale for clinical actionability of molecular targets (ESCAT). Ann Oncol. 2018;29(9):1895–1902.
Li MM, Datto M, Duncavage EJ, Kulkarni S, Lindeman NI, Roy S, et al. Standards and guidelines for the interpretation and reporting of sequence variants in cancer: a joint consensus recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists. J Mol Diagn. 2017;19(1):4–23.
Horak P, Griffith M, Danos AM, Pitel BA, Madhavan S, Liu X, et al. Standards for the classification of pathogenicity of somatic variants in cancer (oncogenicity): joint recommendations of Clinical Genome Resource (ClinGen), Cancer Genomics Consortium (CGC), and Variant Interpretation for Cancer Consortium (VICC). Genet Med. 2022;24(5):986–998.
Larkin J, Ascierto PA, Dréno B, Atkinson V, Liszkay G, Maio M, et al. Combined vemurafenib and cobimetinib in BRAF‐mutated melanoma. N Engl J Med. 2014;371(20):1867–1876.
Long GV, Stroyakovskiy D, Gogas H, Levchenko E, De Braud F, Larkin J, et al. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N Engl J Med. 2014;371(20):1877–1888.
Long GV, Hauschild A, Santinami M, Atkinson V, Mandalà M, Chiarion‐Sileni V, et al. Adjuvant dabrafenib plus trametinib in stage III BRAF‐mutated melanoma. N Engl J Med. 2017;377(19):1813–1823.
Robert C, Grob JJ, Stroyakovskiy D, Karaszewska B, Hauschild A, Levchenko E, et al. Five‐year outcomes with dabrafenib plus trametinib in metastatic melanoma. N Engl J Med. 2019;381(7):626–636.
Dummer R, Ascierto PA, Gogas HJ, Arance A, Mandala M, Liszkay G, et al. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF‐mutant melanoma (COLUMBUS): a multicentre, open‐label, randomised phase 3 trial. Lancet Oncol. 2018;19(5):603–615.
Hanna NH, Robinson AG, Temin S, Baker S, Brahmer JR, Ellis PM, et al. Therapy for stage IV non‐small‐cell lung cancer with driver alterations: ASCO and OH (CCO) joint guideline update. J Clin Oncol. 2021;39(9):1040–1091.
Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, Pienkowski T, et al. Lapatinib plus capecitabine for HER2‐positive advanced breast cancer. N Engl J Med. 2006;355(26):2733–2743.
Martin M, Holmes FA, Ejlertsen B, Delaloge S, Moy B, Iwata H, et al. Neratinib after trastuzumab‐based adjuvant therapy in HER2‐positive breast cancer (ExteNET): 5‐year analysis of a randomised, double‐blind, placebo‐controlled, phase 3 trial. Lancet Oncol. 2017;18(12):1688–1700.
Murthy RK, Loi S, Okines A, Paplomata E, Hamilton E, Hurvitz SA, et al. Tucatinib, trastuzumab, and capecitabine for HER2‐positive metastatic breast cancer. N Engl J Med. 2020;382(7):597–609.
Early Breast Cancer Trialists' Collaborative group (EBCTCG). Trastuzumab for early‐stage, HER2‐positive breast cancer: a meta‐analysis of 13 864 women in seven randomised trials. Lancet Oncol. 2021;22(8):1139–1150.
Piccart M, Procter M, Fumagalli D, de Azambuja E, Clark E, Ewer MS, et al. Adjuvant pertuzumab and trastuzumab in early HER2‐positive breast cancer in the APHINITY trial: 6 years' follow‐up. J Clin Oncol. 2021;39(13):1448–1457.
Rugo HS, Im S‐A, Cardoso F, Cortés J, Curigliano G, Musolino A, et al. Efficacy of margetuximab vs trastuzumab in patients with pretreated ERBB2‐positive advanced breast cancer: a phase 3 randomized clinical trial. JAMA Oncol. 2021;7(4):573–584.
Javle M, Lowery M, Shroff RT, Weiss KH, Springfeld C, Borad MJ, et al. Phase II study of BGJ398 in patients with FGFR‐altered advanced cholangiocarcinoma. J Clin Oncol. 2018;36(3):276–282.
Abou‐Alfa GK, Sahai V, Hollebecque A, Vaccaro G, Melisi D, Al‐Rajabi R, et al. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open‐label, phase 2 study. Lancet Oncol. 2020;21(5):671–684.
Siefker‐Radtke AO, Necchi A, Park SH, García‐Donas J, Huddart RA, Burgess EF, et al. Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long‐term follow‐up of a phase 2 study. Lancet Oncol. 2022;23(2):248–258.
Kelly CM, Gutierrez Sainz L, Chi P. The management of metastatic GIST: current standard and investigational therapeutics. J Hematol Oncol. 2021;14(1):2.
Desilets A, Repetto M, Yang S‐R, Sherman EJ, Drilon A. RET‐altered cancers‐a tumor‐agnostic review of biology, diagnosis and targeted therapy activity. Cancers (Basel). 2023;15(16):4146.
Sforza V, Palumbo G, Cascetta P, Carillio G, Manzo A, Montanino A, et al. BRAF inhibitors in non‐small cell lung cancer. Cancers (Basel). 2022;14(19):4863.
Wen PY, Stein A, van den Bent M, De Greve J, Wick A, de Vos FYFL, et al. Dabrafenib plus trametinib in patients with BRAFV600E‐mutant low‐grade and high‐grade glioma (ROAR): a multicentre, open‐label, single‐arm, phase 2, basket trial. Lancet Oncol. 2022;23(1):53–64.
Iannantuono GM, Riondino S, Sganga S, Rosenfeld R, Guerriero S, Carlucci M, et al. NTRK gene fusions in solid tumors and TRK inhibitors: a systematic review of case reports and case series. J Pers Med. 2022;12(11):1819.
Lin B, Ziebro J, Smithberger E, Skinner KR, Zhao E, Cloughesy TF, et al. EGFR, the Lazarus target for precision oncology in glioblastoma. Neuro Oncol. 2022;24(12):2035–2062.
Stummer W, Pichlmeier U, Meinel T, Wiestler OD, Zanella F, Reulen H‐J, et al. Fluorescence‐guided surgery with 5‐aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol. 2006;7(5):392–401.
Walker MD, Alexander E, Hunt WE, MacCarty CS, Mahaley MS, Mealey J, et al. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. J Neurosurg. 1978;49(3):333–343.
Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJB, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987–996.
Wen PY, Weller M, Lee EQ, Alexander BM, Barnholtz‐Sloan JS, Barthel FP, et al. Glioblastoma in adults: a Society for Neuro‐Oncology (SNO) and European Society of Neuro‐Oncology (EANO) consensus review on current management and future directions. Neuro Oncol. 2020;22(8):1073–1113.
Stupp R, Taillibert S, Kanner A, Read W, Steinberg D, Lhermitte B, et al. Effect of tumor‐treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial. JAMA. 2017;318(23):2306–2316.
Weller M, Le Rhun E. How did lomustine become standard of care in recurrent glioblastoma? Cancer Treat Rev. 2020;87:102029.
Herrlinger U, Tzaridis T, Mack F, Steinbach JP, Schlegel U, Sabel M, et al. Lomustine‐temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA‐09): a randomised, open‐label, phase 3 trial. Lancet. 2019;393(10172):678–688.
Wick W, Gorlia T, Bendszus M, Taphoorn M, Sahm F, Harting I, et al. Lomustine and bevacizumab in progressive glioblastoma. N Engl J Med. 2017;377(20):1954–1963.
Karschnia P, Dono A, Young JS, Juenger ST, Teske N, Häni L, et al. Prognostic evaluation of re‐resection for recurrent glioblastoma using the novel RANO classification for extent of resection: a report of the RANO resect group. Neuro Oncol. 2023;25(9):1672–1685.
Tsien CI, Pugh SL, Dicker AP, Raizer JJ, Matuszak MM, Lallana EC, et al. NRG oncology/RTOG1205: a randomized phase II trial of concurrent bevacizumab and reirradiation versus bevacizumab alone as treatment for recurrent glioblastoma. J Clin Oncol. 2023;41(6):1285–1295.
Lombardi G, De Salvo GL, Brandes AA, Eoli M, Rudà R, Faedi M, et al. Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): a multicentre, open‐label, randomised, controlled, phase 2 trial. Lancet Oncol. 2019;20(1):110–119.
Esteller M, Garcia‐Foncillas J, Andion E, Goodman SN, Hidalgo OF, Vanaclocha V, et al. Inactivation of the DNA‐repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med. 2000;343(19):1350–1354.
Hegi ME, Diserens A‐C, Gorlia T, Hamou M‐F, de Tribolet N, Weller M, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005;352(10):997–1003.
Stupp R, Hegi ME, Gorlia T, Erridge SC, Perry J, Hong Y‐K, et al. Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071‐22072 study): a multicentre, randomised, open‐label, phase 3 trial. Lancet Oncol. 2014;15(10):1100–1108.
Lim M, Weller M, Idbaih A, Steinbach J, Finocchiaro G, Raval RR, et al. Phase 3 trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter. Neuro Oncol. 2022;24:1935–1949.
Herrlinger U, Schäfer N, Steinbach JP, Weyerbrock A, Hau P, Goldbrunner R, et al. Bevacizumab plus irinotecan versus temozolomide in newly diagnosed O6‐methylguanine‐DNA methyltransferase nonmethylated glioblastoma: the randomized GLARIUS trial. J Clin Oncol. 2016;34(14):1611–1619.
Perry JR, Laperriere N, O'Callaghan CJ, Brandes AA, Menten J, Phillips C, et al. Short‐course radiation plus temozolomide in elderly patients with glioblastoma. N Engl J Med. 2017;376(11):1027–1037.
Wick W, Gorlia T, Bady P, Platten M, van den Bent MJ, Taphoorn MJB, et al. Phase II study of radiotherapy and temsirolimus versus radiochemotherapy with temozolomide in patients with newly diagnosed glioblastoma without MGMT promoter hypermethylation (EORTC 26082). Clin Cancer Res. 2016;22(19):4797–4806.
Capper D, Jones DTW, Sill M, Hovestadt V, Schrimpf D, Sturm D, et al. DNA methylation‐based classification of central nervous system tumours. Nature. 2018;555(7697):469–474.
Verhaak RGW, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 2010;17(1):98–110.
Sturm D, Witt H, Hovestadt V, Khuong‐Quang D‐A, Jones DTW, Konermann C, et al. Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. Cancer Cell. 2012;22(4):425–437.
Wick A, Kessler T, Platten M, Meisner C, Bamberg M, Herrlinger U, et al. Superiority of temozolomide over radiotherapy for elderly patients with RTK II methylation class, MGMT promoter methylated malignant astrocytoma. Neuro Oncology. 2020;22(8):1162–1172.
Castro M, Pampana A, Alam A, Parashar R, Rajagopalan S, Lala DA, et al. Combination chemotherapy versus temozolomide for patients with methylated MGMT (m‐MGMT) glioblastoma: results of computational biological modeling to predict the magnitude of treatment benefit. J Neurooncol. 2021;153(3):393–402.
Neftel C, Laffy J, Filbin MG, Hara T, Shore ME, Rahme GJ, et al. An integrative model of cellular states, plasticity, and genetics for glioblastoma. Cell. 2019;178(4):835–849.e21.
Hoogstrate Y, Draaisma K, Ghisai SA, van Hijfte L, Barin N, de Heer I, et al. Transcriptome analysis reveals tumor microenvironment changes in glioblastoma. Cancer Cell. 2023;41(4):678–692.e7.
Brennan CW, Verhaak RGW, McKenna A, Campos B, Noushmehr H, Salama SR, et al. The somatic genomic landscape of glioblastoma. Cell. 2013;155(2):462–477.
Stichel D, Ebrahimi A, Reuss D, Schrimpf D, Ono T, Shirahata M, et al. Distribution of EGFR amplification, combined chromosome 7 gain and chromosome 10 loss, and TERT promoter mutation in brain tumors and their potential for the reclassification of IDHwt astrocytoma to glioblastoma. Acta Neuropathol. 2018;136(5):793–803.
Hu H, Mu Q, Bao Z, Chen Y, Liu Y, Chen J, et al. Mutational landscape of secondary glioblastoma guides MET‐targeted trial in brain tumor. Cell. 2018;175(6):1665–1678.e18.
Ferguson SD, Zhou S, Huse JT, de Groot JF, Xiu J, Subramaniam DS, et al. Targetable gene fusions associate with the IDH wild‐type astrocytic lineage in adult gliomas. J Neuropathol Exp Neurol. 2018;77(6):437–442.
Singh D, Chan JM, Zoppoli P, Niola F, Sullivan R, Castano A, et al. Transforming fusions of FGFR and TACC genes in human glioblastoma. Science. 2012;337(6099):1231–1235.
Frattini V, Trifonov V, Chan JM, Castano A, Lia M, Abate F, et al. The integrated landscape of driver genomic alterations in glioblastoma. Nat Genet. 2013;45(10):1141–1149.
The Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature. 2008;455(7216):1061–1068.
Hodges TR, Ott M, Xiu J, Gatalica Z, Swensen J, Zhou S, et al. Mutational burden, immune checkpoint expression, and mismatch repair in glioma: implications for immune checkpoint immunotherapy. Neuro Oncol. 2017;19(8):1047–1057.
Indraccolo S, Lombardi G, Fassan M, Pasqualini L, Giunco S, Marcato R, et al. Genetic, epigenetic, and immunologic profiling of MMR‐deficient relapsed glioblastoma. Clin Cancer Res. 2019;25(6):1828–1837.
Touat M, Li YY, Boynton AN, Spurr LF, Iorgulescu JB, Bohrson CL, et al. Mechanisms and therapeutic implications of hypermutation in gliomas. Nature. 2020;580(7804):517–523.
Johann P, Lenz D, Ries M. The drug development pipeline for glioblastoma – a cross sectional assessment of the FDA orphan drug product designation database. PLoS One. 2021;16(7):e0252924.
Majd NK, Yap TA, Koul D, Balasubramaniyan V, Li X, Khan S, et al. The promise of DNA damage response inhibitors for the treatment of glioblastoma. Neurooncol Adv. 2021;3(1):vdab015.
Juratli TA, Kirsch M, Robel K, Soucek S, Geiger K, von Kummer R, et al. IDH mutations as an early and consistent marker in low‐grade astrocytomas WHO grade II and their consecutive secondary high‐grade gliomas. J Neurooncol. 2012;108(3):403–410.
Parsons DW, Jones S, Zhang X, Lin JC‐H, Leary RJ, Angenendt P, et al. An integrated genomic analysis of human glioblastoma multiforme. Science. 2008;321(5897):1807–1812.
Ravi VM, Will P, Kueckelhaus J, Sun N, Joseph K, Salié H, et al. Spatially resolved multi‐omics deciphers bidirectional tumor‐host interdependence in glioblastoma. Cancer Cell. 2022;40(6):639–655.e13.
Schäfer N, Gielen GH, Rauschenbach L, Kebir S, Till A, Reinartz R, et al. Longitudinal heterogeneity in glioblastoma: moving targets in recurrent versus primary tumors. J Transl Med. 2019;17(1):96.
Kim J, Lee I‐H, Cho HJ, Park C‐K, Jung Y‐S, Kim Y, et al. Spatiotemporal evolution of the primary glioblastoma genome. Cancer Cell. 2015;28(3):318–328.
Barthel FP, Johnson KC, Varn FS, Moskalik AD, Tanner G, Kocakavuk E, et al. Longitudinal molecular trajectories of diffuse glioma in adults. Nature. 2019;576(7785):112–120.
Körber V, Yang J, Barah P, Wu Y, Stichel D, Gu Z, et al. Evolutionary trajectories of IDHWT glioblastomas reveal a common path of early tumorigenesis instigated years ahead of initial diagnosis. Cancer Cell. 2019;35(4):692–704.e12.
Brandes AA, Carpentier AF, Kesari S, Sepulveda‐Sanchez JM, Wheeler HR, Chinot O, et al. A phase II randomized study of galunisertib monotherapy or galunisertib plus lomustine compared with lomustine monotherapy in patients with recurrent glioblastoma. Neuro Oncol. 2016;18(8):1146–1156.
Wick W, Fricke H, Junge K, Kobyakov G, Martens T, Heese O, et al. A phase II, randomized, study of weekly APG101+reirradiation versus reirradiation in progressive glioblastoma. Clin Cancer Res. 2014;20(24):6304–6313.
Franceschi E, Stupp R, van den Bent MJ, van Herpen C, Laigle Donadey F, Gorlia T, et al. EORTC 26083 phase I/II trial of dasatinib in combination with CCNU in patients with recurrent glioblastoma. Neuro Oncol. 2012;14(12):1503–1510.
Galanis E, Anderson SK, Twohy EL, Carrero XW, Dixon JG, Tran DD, et al. A phase 1 and randomized, placebo‐controlled phase 2 trial of bevacizumab plus dasatinib in patients with recurrent glioblastoma: Alliance/North Central Cancer Treatment Group N0872. Cancer. 2019;125(21):3790–3800.
Lassman AB, Pugh SL, Gilbert MR, Aldape KD, Geinoz S, Beumer JH, et al. Phase 2 trial of dasatinib in target‐selected patients with recurrent glioblastoma (RTOG 0627). Neuro Oncol. 2015;17(7):992–998.
de Groot J, Ott M, Wei J, Kassab C, Fang D, Najem H, et al. A first‐in‐human phase I trial of the oral p‐STAT3 inhibitor WP1066 in patients with recurrent malignant glioma. CNS Oncol. 2022;11(2):CNS87.
Wen PY, Schiff D, Cloughesy TF, Raizer JJ, Laterra J, Smitt M, et al. A phase II study evaluating the efficacy and safety of AMG 102 (rilotumumab) in patients with recurrent glioblastoma. Neuro Oncol. 2011;13(4):437–446.
Bota DA, Mason W, Kesari S, Magge R, Winograd B, Elias I, et al. Marizomib alone or in combination with bevacizumab in patients with recurrent glioblastoma: phase I/II clinical trial data. Neurooncol Adv. 2021;3(1):vdab142.
Weaver M, Laske DW. Transferrin receptor ligand‐targeted toxin conjugate (Tf‐CRM107) for therapy of malignant gliomas. J Neurooncol. 2003;65(1):3–13.
Laske DW, Youle RJ, Oldfield EH. Tumor regression with regional distribution of the targeted toxin TF‐CRM107 in patients with malignant brain tumors. Nat Med. 1997;3(12):1362–1368.
Sampson JH, Singh Achrol A, Aghi MK, Bankiewicz K, Bexon M, Brem S, et al. Targeting the IL4 receptor with MDNA55 in patients with recurrent glioblastoma: results of a phase IIb trial. Neuro Oncol. 2023;25(6):1085–1097.
Wick W, Dettmer S, Berberich A, Kessler T, Karapanagiotou‐Schenkel I, Wick A, et al. N2M2 (NOA‐20) phase I/II trial of molecularly matched targeted therapies plus radiotherapy in patients with newly diagnosed non‐MGMT hypermethylated glioblastoma. Neuro Oncol. 2019;21(1):95–105.
Wen P, Alexander B, Berry D, Buxton M, Cavenee W, Colman H, et al. CTNI‐85. GBM agile platform trial for newly diagnosed and recurrent GBM: results of first experimental arm, regorafenib. Neuro Oncol. 2023;25(Suppl 5):v97–v98.
Tzaridis T, Gepfner‐Tuma I, Hirsch S, Skardelly M, Bender B, Paulsen F, et al. Regorafenib in advanced high‐grade glioma: a retrospective bicentric analysis. Neuro Oncol. 2019;21(7):954–955.
Santangelo A, Rossato M, Lombardi G, Benfatto S, Lavezzari D, De Salvo GL, et al. A molecular signature associated with prolonged survival in glioblastoma patients treated with regorafenib. Neuro Oncol. 2021;23(2):264–276.
Krueger DA, Care MM, Holland K, Agricola K, Tudor C, Mangeshkar P, et al. Everolimus for subependymal giant‐cell astrocytomas in tuberous sclerosis. N Engl J Med. 2010;363(19):1801–1811.
Mellinghoff IK, van den Bent MJ, Blumenthal DT, Touat M, Peters KB, Clarke J, et al. Vorasidenib in IDH1‐ or IDH2‐mutant low‐grade glioma. N Engl J Med. 2023;389(7):589–601.
Capper D, Reifenberger G, French PJ, Schweizer L, Weller M, Touat M, et al. EANO guideline on rational molecular testing of gliomas, glioneuronal, and neuronal tumors in adults for targeted therapy selection. Neuro Oncol. 2023;25(5):813–826.
Laetsch TW, DuBois SG, Mascarenhas L, Turpin B, Federman N, Albert CM, et al. Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open‐label, phase 1/2 study. Lancet Oncol. 2018;19(5):705–714.
Doz F, van Tilburg CM, Geoerger B, Højgaard M, Øra I, Boni V, et al. Efficacy and safety of larotrectinib in TRK fusion‐positive primary central nervous system tumors. Neuro Oncol. 2022;24(6):997–1007.
Marabelle A, Le DT, Ascierto PA, Di Giacomo AM, De Jesus‐Acosta A, Delord J‐P, et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair‐deficient cancer: results from the phase II KEYNOTE‐158 study. J Clin Oncol. 2020;38(1):1–10.
Omuro A, Brandes AA, Carpentier AF, Idbaih A, Reardon DA, Cloughesy T, et al. Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: an international randomized phase III trial. Neuro Oncol. 2023;25(1):123–134.
Reardon DA, Brandes AA, Omuro A, Mulholland P, Lim M, Wick A, et al. Effect of nivolumab vs bevacizumab in patients with recurrent glioblastoma: the CheckMate 143 phase 3 randomized clinical trial. JAMA Oncol. 2020;6(7):1003–1010.
Lassman AB, Pugh SL, Wang TJC, Aldape K, Gan HK, Preusser M, et al. Depatuxizumab mafodotin in EGFR‐amplified newly diagnosed glioblastoma: a phase III randomized clinical trial. Neuro Oncol. 2023;25(2):339–350.
Weller M, Butowski N, Tran DD, Recht LD, Lim M, Hirte H, et al. Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII‐expressing glioblastoma (ACT IV): a randomised, double‐blind, international phase 3 trial. Lancet Oncol. 2017;18(10):1373–1385.
Ellingson BM, Wen PY, Chang SM, van den Bent M, Vogelbaum MA, Li G, et al. Objective response rate targets for recurrent glioblastoma clinical trials based on the historic association between objective response rate and median overall survival. Neuro Oncol. 2023;25(6):1017–1028.
Lamborn KR, Yung WKA, Chang SM, Wen PY, Cloughesy TF, DeAngelis LM, et al. Progression‐free survival: an important end point in evaluating therapy for recurrent high‐grade gliomas. Neuro Oncol. 2008;10(2):162–170.
Lassman AB, Aldape KD, Ansell PJ, Bain E, Curran WJ, Eoli M, et al. Epidermal growth factor receptor (EGFR) amplification rates observed in screening patients for randomized trials in glioblastoma. J Neurooncol. 2019;144(1):205–210.
Hu C, Leche CA, Kiyatkin A, Yu Z, Stayrook SE, Ferguson KM, et al. Glioblastoma mutations alter EGFR dimer structure to prevent ligand bias. Nature. 2022;602(7897):518–522.
Mukasa A, Wykosky J, Ligon KL, Chin L, Cavenee WK, Furnari F. Mutant EGFR is required for maintenance of glioma growth in vivo, and its ablation leads to escape from receptor dependence. Proc Natl Acad Sci USA. 2010;107(6):2616–2621.
Francis JM, Zhang C‐Z, Maire CL, Jung J, Manzo VE, Adalsteinsson VA, et al. EGFR variant heterogeneity in glioblastoma resolved through single‐nucleus sequencing. Cancer Discov. 2014;4(8):956–971.
Cheng Y‐K, Beroukhim R, Levine RL, Mellinghoff IK, Holland EC, Michor F. A mathematical methodology for determining the temporal order of pathway alterations arising during gliomagenesis. PLoS Comput Biol. 2012;8(1):e1002337.
Snuderl M, Fazlollahi L, Le LP, Nitta M, Zhelyazkova BH, Davidson CJ, et al. Mosaic amplification of multiple receptor tyrosine kinase genes in glioblastoma. Cancer Cell. 2011;20(6):810–817.
Inda M‐M, Bonavia R, Mukasa A, Narita Y, Sah DWY, Vandenberg S, et al. Tumor heterogeneity is an active process maintained by a mutant EGFR‐induced cytokine circuit in glioblastoma. Genes Dev. 2010;24(16):1731–1745.
Johnson BE, Mazor T, Hong C, Barnes M, Aihara K, McLean CY, et al. Mutational analysis reveals the origin and therapy‐driven evolution of recurrent glioma. Science. 2014;343(6167):189–193.
van den Bent MJ, Gao Y, Kerkhof M, Kros JM, Gorlia T, van Zwieten K, et al. Changes in the EGFR amplification and EGFRvIII expression between paired primary and recurrent glioblastomas. Neuro Oncol. 2015;17(7):935–941.
Colclough N, Chen K, Johnström P, Strittmatter N, Yan Y, Wrigley GL, et al. Preclinical comparison of the blood–brain barrier permeability of osimertinib with other EGFR TKIs. Clin Cancer Res. 2021;27(1):189–201.
Tsang JE, Urner LM, Kim G, Chow K, Baufeld L, Faull K, et al. Development of a potent brain‐penetrant EGFR tyrosine kinase inhibitor against malignant brain tumors. ACS Med Chem Lett. 2020;11(10):1799–1809.
Hegi ME, Diserens A‐C, Bady P, Kamoshima Y, Kouwenhoven MCM, Delorenzi M, et al. Pathway analysis of glioblastoma tissue after preoperative treatment with the EGFR tyrosine kinase inhibitor gefitinib – a phase II trial. Mol Cancer Ther. 2011;10(6):1102–1112.
Mellinghoff IK, Wang MY, Vivanco I, Haas‐Kogan DA, Zhu S, Dia EQ, et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med. 2005;353(19):2012–2024.
Alexander BM, Trippa L, Gaffey S, Arrillaga‐Romany IC, Lee EQ, Rinne ML, et al. Individualized screening trial of innovative glioblastoma therapy (INSIGhT): a Bayesian adaptive platform trial to develop precision medicines for patients with glioblastoma. JCO Precis Oncol. 2019;3:1–13.
Alexander BM, Ba S, Berger MS, Berry DA, Cavenee WK, Chang SM, et al. Adaptive global innovative learning environment for glioblastoma: GBM AGILE. Clin Cancer Res. 2018;24(4):737–743.
Rahman R, Trippa L, Lee EQ, Arrillaga‐Romany I, Fell G, Touat M, et al. Inaugural results of the individualized screening trial of innovative glioblastoma therapy: a phase II platform trial for newly diagnosed glioblastoma using Bayesian adaptive randomization. J Clin Oncol. 2023;41:5524–5535.
Tsimberidou A‐M, Hong DS, Wheler JJ, Falchook GS, Janku F, Naing A, et al. Long‐term overall survival and prognostic score predicting survival: the IMPACT study in precision medicine. J Hematol Oncol. 2019;12(1):145.
Tsimberidou AM, Hong DS, Fu S, Karp DD, Piha‐Paul S, Kies MS, et al. Precision medicine: preliminary results from the initiative for molecular profiling and advanced cancer therapy 2 (IMPACT2) study. NPJ Precis Oncol. 2021;5(1):21.
Taylor JW, Parikh M, Phillips JJ, James CD, Molinaro AM, Butowski NA, et al. Phase‐2 trial of palbociclib in adult patients with recurrent RB1‐positive glioblastoma. J Neurooncol. 2018;140(2):477–483.
Cen L, Carlson BL, Schroeder MA, Ostrem JL, Kitange GJ, Mladek AC, et al. p16‐Cdk4‐Rb axis controls sensitivity to a cyclin‐dependent kinase inhibitor PD0332991 in glioblastoma xenograft cells. Neuro Oncol. 2012;14(7):870–881.
Leichsenring J, Horak P, Kreutzfeldt S, Heining C, Christopoulos P, Volckmar A‐L, et al. Variant classification in precision oncology. Int J Cancer. 2019;145(11):2996–3010.
Horak P, Heining C, Kreutzfeldt S, Hutter B, Mock A, Hüllein J, et al. Comprehensive genomic and transcriptomic analysis for guiding therapeutic decisions in patients with rare cancers. Cancer Discov. 2021;11(11):2780–2795.
Von Hoff DD, Stephenson JJ, Rosen P, Loesch DM, Borad MJ, Anthony S, et al. Pilot study using molecular profiling of patients' tumors to find potential targets and select treatments for their refractory cancers. J Clin Oncol. 2010;28(33):4877–4883.
Mock A, Heilig CE, Kreutzfeldt S, Huebschmann D, Heining C, Schröck E, et al. Community‐driven development of a modified progression‐free survival ratio for precision oncology. ESMO Open. 2019;4(6):e000583.
Renovanz M, Kurz SC, Rieger J, Walter B, Becker H, Hille H, et al. Clinical outcome of biomarker‐guided therapies in adult patients with tumors of the nervous system. Neurooncol Adv. 2023;5(1):vdad012.
Padovan M, Maccari M, Bosio A, De Toni C, Vizzaccaro S, Cestonaro I, et al. Actionable molecular alterations in newly diagnosed and recurrent IDH1/2 wild‐type glioblastoma patients and therapeutic implications: a large mono‐institutional experience using extensive next‐generation sequencing analysis. Eur J Cancer. 2023;191:112959.
Blumenthal DT, Dvir A, Lossos A, Tzuk‐Shina T, Lior T, Limon D, et al. Clinical utility and treatment outcome of comprehensive genomic profiling in high grade glioma patients. J Neurooncol. 2016;130(1):211–219.
Byron SA, Tran NL, Halperin RF, Phillips JJ, Kuhn JG, de Groot JF, et al. Prospective feasibility trial for genomics‐informed treatment in recurrent and progressive glioblastoma. Clin Cancer Res. 2018;24(2):295–305.
Lazaridis L, Schmidt T, Oster C, Blau T, Pierscianek D, Siveke JT, et al. Precision neuro‐oncology: a pilot analysis of personalized treatment in recurrent glioma. J Cancer Res Clin Oncol. 2023;149(7):3513–3526.
Chinot OL, Wick W, Mason W, Henriksson R, Saran F, Nishikawa R, et al. Bevacizumab plus radiotherapy‐temozolomide for newly diagnosed glioblastoma. N Engl J Med. 2014;370(8):709–722.
Van Den Bent M, Eoli M, Sepulveda JM, Smits M, Walenkamp A, Frenel J‐S, et al. INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux‐M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma. Neuro Oncol. 2020;22(5):684–693.
Lorenz J, Rothhammer‐Hampl T, Zoubaa S, Bumes E, Pukrop T, Kölbl O, et al. A comprehensive DNA panel next generation sequencing approach supporting diagnostics and therapy prediction in neurooncology. Acta Neuropathol Commun. 2020;8(1):124.
Kessler T, Berberich A, Casalini B, Drüschler K, Ostermann H, Dormann A, et al. Molecular profiling‐based decision for targeted therapies in IDH wild‐type glioblastoma. Neurooncol Adv. 2020;2(1):vdz060.
Luger A‐L, König S, Samp PF, Urban H, Divé I, Burger MC, et al. Molecular matched targeted therapies for primary brain tumors‐a single center retrospective analysis. J Neurooncol. 2022;159(2):243–259.
Rodon J, Soria J‐C, Berger R, Miller WH, Rubin E, Kugel A, et al. Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial. Nat Med. 2019;25(5):751–758.
Migliozzi S, Oh YT, Hasanain M, Garofano L, D'Angelo F, Najac RD, et al. Integrative multi‐omics networks identify PKCδ and DNA‐PK as master kinases of glioblastoma subtypes and guide targeted cancer therapy. Nat Cancer. 2023;4(2):181–202.
Mair MJ, Bartsch R, Le Rhun E, Berghoff AS, Brastianos PK, Cortes J, et al. Understanding the activity of antibody–drug conjugates in primary and secondary brain tumours. Nat Rev Clin Oncol. 2023;20(6):372–389.
Karschnia P, Teske N, Thon N, Subklewe M, Tonn J‐C, Dietrich J, et al. Chimeric antigen receptor T cells for glioblastoma: current concepts, challenges, and future perspectives. Neurology. 2021;97(5):218–230.
Burger MC, Forster M‐T, Romanski A, Straßheimer F, Macas J, Zeiner PS, et al. Intracranial injection of NK cells engineered with a HER2‐targeted chimeric antigen receptor in patients with recurrent glioblastoma. Neuro Oncol. 2023;25:2058–2071.
Coy S, Lee JS, Chan SJ, Woo T, Jones J, Alexandrescu S, et al. Systematic characterization of antibody‐drug conjugate targets in central nervous system tumors. Neuro Oncol. 2024;26:458–472.
Rothwell DG, Ayub M, Cook N, Thistlethwaite F, Carter L, Dean E, et al. Utility of ctDNA to support patient selection for early phase clinical trials: the TARGET study. Nat Med. 2019;25(5):738–743.
Zachariah MA, Oliveira‐Costa JP, Carter BS, Stott SL, Nahed BV. Blood‐based biomarkers for the diagnosis and monitoring of gliomas. Neuro Oncol. 2018;20(9):1155–1161.
Aldea M, Andre F, Marabelle A, Dogan S, Barlesi F, Soria J‐C. Overcoming resistance to tumor‐targeted and immune‐targeted therapies. Cancer Discov. 2021;11(4):874–899.
Kim Y, Armstrong TS, Gilbert MR, Celiku O. A critical analysis of neuro‐oncology clinical trials. Neuro Oncol. 2023;25(9):1658–1671.
Song K‐W, Wen PY. Novel trial designs in neuro‐oncology. Curr Opin Neurol. 2023;36:571–578. https://doi.org/10.1097/WCO.0000000000001210
Karimi E, Yu MW, Maritan SM, Perus LJM, Rezanejad M, Sorin M, et al. Single‐cell spatial immune landscapes of primary and metastatic brain tumours. Nature. 2023;614(7948):555–563.
Soffietti R, Bettegowda C, Mellinghoff IK, Warren KE, Ahluwalia MS, De Groot JF, et al. Liquid biopsy in gliomas: a RANO review and proposals for clinical applications. Neuro Oncol. 2022;24(6):855–871.
Maire CL, Fuh MM, Kaulich K, Fita KD, Stevic I, Heiland DH, et al. Genome‐wide methylation profiling of glioblastoma cell‐derived extracellular vesicle DNA allows tumor classification. Neuro Oncol. 2021;23(7):1087–1099.
Tzaridis T, Reiners KS, Weller J, Bachurski D, Schäfer N, Schaub C, et al. Analysis of serum miRNA in glioblastoma patients: CD44‐based enrichment of extracellular vesicles enhances specificity for the prognostic signature. Int J Mol Sci. 2020;21(19):E7211.
Shao H, Chung J, Lee K, Balaj L, Min C, Carter BS, et al. Chip‐based analysis of exosomal mRNA mediating drug resistance in glioblastoma. Nat Commun. 2015;6:6999.
Batool SM, Muralidharan K, Hsia T, Falotico S, Gamblin AS, Rosenfeld YB, et al. Highly sensitive EGFRvIII detection in circulating extracellular vesicle RNA of glioma patients. Clin Cancer Res. 2022;28(18):4070–4082.
Westphal M, Lamszus K. Circulating biomarkers for gliomas. Nat Rev Neurol. 2015;11(10):556–566.
Broekman ML, Maas SLN, Abels ER, Mempel TR, Krichevsky AM, Breakefield XO. Multidimensional communication in the microenvirons of glioblastoma. Nat Rev Neurol. 2018;14(8):482–495.
Yekula A, Yekula A, Muralidharan K, Kang K, Carter BS, Balaj L. Extracellular vesicles in glioblastoma tumor microenvironment. Front Immunol. 2019;10:3137.
Zhan Q, Yi K, Cui X, Li X, Yang S, Wang Q, et al. Blood exosomes‐based targeted delivery of cPLA2 siRNA and metformin to modulate glioblastoma energy metabolism for tailoring personalized therapy. Neuro Oncol. 2022;24(11):1871–1883.
Rehman FU, Liu Y, Zheng M, Shi B. Exosomes based strategies for brain drug delivery. Biomaterials. 2023;293:121949.
Gilbert MR, Dignam JJ, Armstrong TS, Wefel JS, Blumenthal DT, Vogelbaum MA, et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med. 2014;370(8):699–708.
Batchelor TT, Mulholland P, Neyns B, Nabors LB, Campone M, Wick A, et al. Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma. J Clin Oncol. 2013;31(26):3212–3218.
Batchelor TT, Won M, Chakravarti A, Hadjipanayis CG, Shi W, Ashby LS, et al. NRG/RTOG 0837: randomized, phase II, double‐blind, placebo‐controlled trial of chemoradiation with or without cediranib in newly diagnosed glioblastoma. Neurooncol Adv. 2023;5(1):vdad116.
Nabors LB, Fink KL, Mikkelsen T, Grujicic D, Tarnawski R, Nam DH, et al. Two cilengitide regimens in combination with standard treatment for patients with newly diagnosed glioblastoma and unmethylated MGMT gene promoter: results of the open‐label, controlled, randomized phase II CORE study. Neuro Oncol. 2015;17(5):708–717.
Sandmann T, Bourgon R, Garcia J, Li C, Cloughesy T, Chinot OL, et al. Patients with proneural glioblastoma may derive overall survival benefit from the addition of bevacizumab to first‐line radiotherapy and temozolomide: retrospective analysis of the AVAglio trial. J Clin Oncol. 2015;33(25):2735–2744.
Kessler T, Schrimpf D, Doerner L, Hai L, Kaulen LD, Ito J, et al. Prognostic markers of DNA methylation and NGS sequencing in progressive glioblastoma from the EORTC‐26101 trial. Clin Cancer Res. 2023;29:3892–3900.
Weller J, Zeyen T, Schäfer N, Schaub C, Potthoff A‐L, Steinbach JP, et al. The proneural subtype is not associated with survival benefit from bevacizumab in newly diagnosed glioblastoma: a secondary analysis of the GLARIUS trial. J Neurooncol. 2023;164(3):749–755.
Liau LM, Ashkan K, Brem S, Campian JL, Trusheim JE, Iwamoto FM, et al. Association of autologous tumor lysate‐loaded dendritic cell vaccination with extension of survival among patients with newly diagnosed and recurrent glioblastoma: a phase 3 prospective externally controlled cohort trial. JAMA Oncol. 2022;9:112–121.
Ahluwalia MS, Reardon DA, Abad AP, Curry WT, Wong ET, Figel SA, et al. Phase IIa study of SurVaxM plus adjuvant temozolomide for newly diagnosed glioblastoma. J Clin Oncol. 2023;41(7):1453–1465.
Hilf N, Kuttruff‐Coqui S, Frenzel K, Bukur V, Stevanović S, Gouttefangeas C, et al. Actively personalized vaccination trial for newly diagnosed glioblastoma. Nature. 2019;565(7738):240–245.
Schmitt MJ, Company C, Dramaretska Y, Barozzi I, Göhrig A, Kertalli S, et al. Phenotypic mapping of pathologic cross‐talk between glioblastoma and innate immune cells by synthetic genetic tracing. Cancer Discov. 2021;11(3):754–777.
Pyonteck SM, Akkari L, Schuhmacher AJ, Bowman RL, Sevenich L, Quail DF, et al. CSF‐1R inhibition alters macrophage polarization and blocks glioma progression. Nat Med. 2013;19(10):1264–1272.
Butowski N, Colman H, De Groot JF, Omuro AM, Nayak L, Wen PY, et al. Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: an Ivy Foundation Early Phase Clinical Trials Consortium phase II study. Neuro Oncol. 2016;18(4):557–564.
Akkari L, Bowman RL, Tessier J, Klemm F, Handgraaf SM, de Groot M, et al. Dynamic changes in glioma macrophage populations after radiotherapy reveal CSF‐1R inhibition as a strategy to overcome resistance. Sci Transl Med. 2020;12(552):eaaw7843.
Giordano FA, Link B, Glas M, Herrlinger U, Wenz F, Umansky V, et al. Targeting the post‐irradiation tumor microenvironment in glioblastoma via inhibition of CXCL12. Cancers (Basel). 2019;11(3):272.
Thomas RP, Nagpal S, Iv M, Soltys SG, Bertrand S, Pelpola JS, et al. Macrophage exclusion after radiation therapy (MERT): a first in human phase I/II trial using a CXCR4 inhibitor in glioblastoma. Clin Cancer Res. 2019;25(23):6948–6957.
Lin Y‐J, Wu CY‐J, Wu JY, Lim M. The role of myeloid cells in GBM immunosuppression. Front Immunol. 2022;13:887781.
Weiss T, Puca E, Silginer M, Hemmerle T, Pazahr S, Bink A, et al. Immunocytokines are a promising immunotherapeutic approach against glioblastoma. Sci Transl Med. 2020;12(564):eabb2311.
Look T, Puca E, Bühler M, Kirschenbaum D, De Luca R, Stucchi R, et al. Targeted delivery of tumor necrosis factor in combination with CCNU induces a T cell–dependent regression of glioblastoma. Sci Transl Med. 2023;15(697):eadf2281.
Venkatesh HS, Johung TB, Caretti V, Noll A, Tang Y, Nagaraja S, et al. Neuronal activity promotes glioma growth through neuroligin‐3 secretion. Cell. 2015;161(4):803–816.
Osswald M, Jung E, Sahm F, Solecki G, Venkataramani V, Blaes J, et al. Brain tumour cells interconnect to a functional and resistant network. Nature. 2015;528(7580):93–98.
Weil S, Osswald M, Solecki G, Grosch J, Jung E, Lemke D, et al. Tumor microtubes convey resistance to surgical lesions and chemotherapy in gliomas. Neuro Oncol. 2017;19(10):1316–1326.
Venkataramani V, Tanev DI, Strahle C, Studier‐Fischer A, Fankhauser L, Kessler T, et al. Glutamatergic synaptic input to glioma cells drives brain tumour progression. Nature. 2019;573(7775):532–538.
Venkataramani V, Yang Y, Schubert MC, Reyhan E, Tetzlaff SK, Wißmann N, et al. Glioblastoma hijacks neuronal mechanisms for brain invasion. Cell. 2022;185(16):2899–2917.e31.
Hausmann D, Hoffmann DC, Venkataramani V, Jung E, Horschitz S, Tetzlaff SK, et al. Autonomous rhythmic activity in glioma networks drives brain tumour growth. Nature. 2023;613(7942):179–186.
Potthoff A‐L, Heiland DH, Evert BO, Almeida FR, Behringer SP, Dolf A, et al. Inhibition of gap junctions sensitizes primary glioblastoma cells for temozolomide. Cancers (Basel). 2019;11(6):858.
Schneider M, Vollmer L, Potthoff A‐L, Ravi VM, Evert BO, Rahman MA, et al. Meclofenamate causes loss of cellular tethering and decoupling of functional networks in glioblastoma. Neuro Oncol. 2021;23(11):1885–1897.
Zeyen T, Potthoff A‐L, Nemeth R, Heiland DH, Burger MC, Steinbach JP, et al. Phase I/II trial of meclofenamate in progressive MGMT‐methylated glioblastoma under temozolomide second‐line therapy—the MecMeth/NOA‐24 trial. Trials. 2022;23(1):57.
Venkatesh HS, Tam LT, Woo PJ, Lennon J, Nagaraja S, Gillespie SM, et al. Targeting neuronal activity‐regulated neuroligin‐3 dependency in high‐grade glioma. Nature. 2017;549(7673):533–537.
Heuer S, Burghaus I, Gose M, Kessler T, Sahm F, Vollmuth P, et al. PerSurge (NOA‐30) phase II trial of perampanel treatment around surgery in patients with progressive glioblastoma. BMC Cancer. 2024;24(1):135.
Sicklick JK, Kato S, Okamura R, Schwaederle M, Hahn ME, Williams CB, et al. Molecular profiling of cancer patients enables personalized combination therapy: the I‐PREDICT study. Nat Med. 2019;25(5):744–750.
van den Bent MJ, Brandes AA, Rampling R, Kouwenhoven MCM, Kros JM, Carpentier AF, et al. Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034. J Clin Oncol. 2009;27(8):1268–1274.
Lassman AB, Rossi MR, Raizer JJ, Abrey LE, Lieberman FS, Grefe CN, et al. Molecular study of malignant gliomas treated with epidermal growth factor receptor inhibitors: tissue analysis from North American Brain Tumor Consortium Trials 01‐03 and 00‐01. Clin Cancer Res. 2005;11(21):7841–7850.
Prados MD, Chang SM, Butowski N, DeBoer R, Parvataneni R, Carliner H, et al. Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma. J Clin Oncol. 2009;27(4):579–584.
Rich JN, Reardon DA, Peery T, Dowell JM, Quinn JA, Penne KL, et al. Phase II trial of gefitinib in recurrent glioblastoma. J Clin Oncol. 2004;22(1):133–142.
Chakravarti A, Wang M, Robins HI, Lautenschlaeger T, Curran WJ, Brachman DG, et al. RTOG 0211: a phase 1/2 study of radiation therapy with concurrent gefitinib for newly diagnosed glioblastoma patients. Int J Radiat Oncol Biol Phys. 2013;85(5):1206–1211.
Vivanco I, Robins HI, Rohle D, Campos C, Grommes C, Nghiemphu PL, et al. Differential sensitivity of glioma‐ versus lung cancer‐specific EGFR mutations to EGFR kinase inhibitors. Cancer Discov. 2012;2(5):458–471.
Thiessen B, Stewart C, Tsao M, Kamel‐Reid S, Schaiquevich P, Mason W, et al. A phase I/II trial of GW572016 (lapatinib) in recurrent glioblastoma multiforme: clinical outcomes, pharmacokinetics and molecular correlation. Cancer Chemother Pharmacol. 2010;65(2):353–361.
Arrillaga‐Romany I, Trippa L, Fell G, Lee EQ, Rahman R, Touat M, et al. CTNI‐05. Preliminary results of the neratinib arm in the individualized screening trial of innovative glioblastoma therapy (insight): a phase II platform trial using Bayesian adaptive randomization. Neuro Oncol. 2021;23(Suppl 6):vi59.
Reardon DA, Nabors LB, Mason WP, Perry JR, Shapiro W, Kavan P, et al. Phase I/randomized phase II study of afatinib, an irreversible ErbB family blocker, with or without protracted temozolomide in adults with recurrent glioblastoma. Neuro Oncol. 2015;17(3):430–439.
Westphal M, Heese O, Steinbach JP, Schnell O, Schackert G, Mehdorn M, et al. A randomised, open label phase III trial with nimotuzumab, an anti‐epidermal growth factor receptor monoclonal antibody in the treatment of newly diagnosed adult glioblastoma. Eur J Cancer. 2015;51(4):522–532.
Neyns B, Sadones J, Joosens E, Bouttens F, Verbeke L, Baurain J‐F, et al. Stratified phase II trial of cetuximab in patients with recurrent high‐grade glioma. Ann Oncol. 2009;20(9):1596–1603.
Sautter L, Hofheinz R, Tuettenberg J, Grimm M, Vajkoczy P, Groden C, et al. Open‐label phase II evaluation of imatinib in primary inoperable or incompletely resected and recurrent glioblastoma. Oncology. 2020;98(1):16–22.
Reardon DA, Dresemann G, Taillibert S, Campone M, van den Bent M, Clement P, et al. Multicentre phase II studies evaluating imatinib plus hydroxyurea in patients with progressive glioblastoma. Br J Cancer. 2009;101(12):1995–2004.
Mehta S, Fiorelli R, Bao X, Pennington‐Krygier C, Derogatis A, Kim S, et al. A phase 0 trial of ceritinib in patients with brain metastases and recurrent glioblastoma. Clin Cancer Res. 2022;28(2):289–297.
Muhic A, Poulsen HS, Sorensen M, Grunnet K, Lassen U. Phase II open‐label study of nintedanib in patients with recurrent glioblastoma multiforme. J Neurooncol. 2013;111(2):205–212.
Wen PY, Drappatz J, de Groot J, Prados MD, Reardon DA, Schiff D, et al. Phase II study of cabozantinib in patients with progressive glioblastoma: subset analysis of patients naive to antiangiogenic therapy. Neuro Oncol. 2018;20(2):249–258.
Cloughesy TF, Drappatz J, de Groot J, Prados MD, Reardon DA, Schiff D, et al. Phase II study of cabozantinib in patients with progressive glioblastoma: subset analysis of patients with prior antiangiogenic therapy. Neuro Oncol. 2018;20(2):259–267.
Martínez‐García M, Velasco G, Pineda E, Gil‐Gil M, Alameda F, Capellades J, et al. Safety and efficacy of Crizotinib in combination with temozolomide and radiotherapy in patients with newly diagnosed glioblastoma: phase Ib GEINO 1402 trial. Cancers (Basel). 2022;14(10):2393.
Chinnaiyan P, Won M, Wen PY, Rojiani AM, Werner‐Wasik M, Shih HA, et al. A randomized phase II study of everolimus in combination with chemoradiation in newly diagnosed glioblastoma: results of NRG oncology RTOG 0913. Neuro Oncol. 2018;20(5):666–673.
Wen PY, De Groot JF, Battiste J, Goldlust SA, Garner JS, Friend J, et al. Paxalisib in patients with newly diagnosed glioblastoma with unmethylated MGMT promoter status: final phase 2 study results. J Clin Oncol. 2022;40(16 Suppl):2047.
Wen PY, Touat M, Alexander BM, Mellinghoff IK, Ramkissoon S, McCluskey CS, et al. Buparlisib in patients with recurrent glioblastoma harboring phosphatidylinositol 3‐kinase pathway activation: an open‐label, multicenter, multi‐arm, phase II trial. J Clin Oncol. 2019;37(9):741–750.
Sim H‐W, McDonald KL, Lwin Z, Barnes EH, Rosenthal M, Foote MC, et al. A randomized phase II trial of veliparib, radiotherapy, and temozolomide in patients with unmethylated MGMT glioblastoma: the VERTU study. Neuro Oncol. 2021;23(10):1736–1749.
Sloan AE, Nock CJ, Ye X, Buerki R, Chang S, Lesser G, et al. ABTC‐0904: targeting glioma stem cells in GBM: a phase 0/II study of hedgehog pathway inhibitor GDC‐0449. J Neurooncol. 2023;161(1):33–43.
Solomón MT, Selva JC, Figueredo J, Vaquer J, Toledo C, Quintanal N, et al. Radiotherapy plus nimotuzumab or placebo in the treatment of high grade glioma patients: results from a randomized, double blind trial. BMC Cancer. 2013;13(1):299.
Rosenthal M, Clement PM, Campone M, Gil‐Gil MJ, DeGroot J, Chinot O, et al. Buparlisib plus carboplatin or lomustine in patients with recurrent glioblastoma: a phase Ib/II, open‐label, multicentre, randomised study. ESMO Open. 2020;5(4):e000672.
Cloughesy T, Ellingson B, Gafita A, Chun S, Filka E, Nghiemphu P, et al. CTNI‐14. Evaluating metabolic alterations in patients with EGFR activated recurrent glioblastoma (RGBM) by inhibiting EGFR with osimertinib. Neuro Oncol. 2021;23(Suppl 6):vi62.
Chi AS, Cahill DP, Reardon DA, Wen PY, Mikkelsen T, Peereboom DM, et al. Exploring predictors of response to dacomitinib in EGFR‐amplified recurrent glioblastoma. JCO Precis Oncol. 2020;4:593–613.
O'Rourke DM, Nasrallah MP, Desai A, Melenhorst JJ, Mansfield K, Morrissette JJD, et al. A single dose of peripherally infused EGFRvIII‐directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma. Sci Transl Med. 2017;9(399):eaaa0984.
Goff SL, Morgan RA, Yang JC, Sherry RM, Robbins PF, Restifo NP, et al. Pilot trial of adoptive transfer of chimeric antigen receptor‐transduced T cells targeting EGFRvIII in patients with glioblastoma. J Immunother. 2019;42(4):126–135.
Reardon DA, Desjardins A, Vredenburgh JJ, O'Rourke DM, Tran DD, Fink KL, et al. Rindopepimut with bevacizumab for patients with relapsed EGFRvIII‐expressing glioblastoma (ReACT): results of a double‐blind randomized phase II trial. Clin Cancer Res. 2020;26(7):1586–1594.
van den Bent M, Azaro A, De Vos F, Sepulveda J, Yung WKA, Wen PY, et al. A phase Ib/II, open‐label, multicenter study of INC280 (capmatinib) alone and in combination with buparlisib (BKM120) in adult patients with recurrent glioblastoma. J Neurooncol. 2020;146(1):79–89.
Cardona AF, Jaramillo‐Velásquez D, Ruiz‐Patiño A, Polo C, Jiménez E, Hakim F, et al. Efficacy of osimertinib plus bevacizumab in glioblastoma patients with simultaneous EGFR amplification and EGFRvIII mutation. J Neurooncol. 2021;154(3):353–364.
Makhlin I, Salinas RD, Zhang D, Jacob F, Ming G‐L, Song H, et al. Clinical activity of the EGFR tyrosine kinase inhibitor osimertinib in EGFR‐mutant glioblastoma. CNS Oncol. 2019;8(3):CNS43.